Cerus
Manufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
1220 Concord Ave Ste 600, Concord, Calif...Phone Number
(925) 288-6000Website
www.cerus.comRevenue
$221.6 MillionStock Symbol
CERSIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Cerus
Headquartered in Concord, California, Cerus develops and commercializes the INTERCEPT Blood System, a pathogenreduction technology used by blood centers and hospitals to inactivate viruses, bacteria, and parasites in blood components (e.g., platelets and plasma), with additional programs in red blood cells.Explore more
Cerus Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cerus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Cerus had a recent Job posting/layoffs
Cerus, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Cerus
Funding: Get notified immidiatlly once Cerus has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Cerus launches new products
Check out if Cerus is spiking on competitors!
Earning: See what the market has to say on Cerus recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Cerus has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Cerus
Compare insights from companies similar to Cerus, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cerus is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cerus is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cerus.
Cerus financials insights
Gather financial insights about Cerus, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
1997
Stock Offering
$21.3M
2010
Debt
$10M
2014
Debt
$30M
2017
Debt
$40M
2019
Debt
$90M
2020
Stock Offering
$63.3M
Unspecified
$14M
2026
Debt
$110M
Cerus Tech Stack
A closer look at the technologies used by Cerus
See more technologies
Most Recent Scoops
Hiring Plans
Cerus has more open roles in Information Technology than it has had at any time in the past 12 months. Technologies mentioned include: Directly. Areas of expertise include: Software Testing, Templates, CSV Import, Computer Systems, Cyber Security, Computer System Validation, and System Implementation.
Hiring Plans
Earnings
Cerus has raised its full-year 2026 product revenue guidance to a range of $229 to $231 million, up from the previous range of $227 to $231 million, representing total year-over-year product revenue growth of 11% to 12% compared to 2025. Additionally, Cerus raised its full-year 2026 IFC revenue guidance to a range of $23 to $25 million, compared to the previous range of $22 to $24 million, representing approximately 40% to 50% growth for IFC.
Earnings, Finance
Earnings
Cerus has reported that Q2 2026 North American product revenue increased 9% compared to the same period in the prior year, while EMEA product revenue increased 10% year-over-year, with favorable foreign currency exchange rates bolstering reported EMEA revenue growth by approximately 2%.
Earnings, Finance
Project
Cerus has submitted the Pre-Market Approval (PMA) application for the INT200 illumination device for platelets to the US FDA, with potential regulatory approval expected as early as H1 2027, subject to the FDA's review process.
Product Development
Project
Medical Research
Cerus News & Media
Cerus Corporation (CERS) Closes New Debt Facility of Up to $110M
Cerus Corporation (NASDAQ:CERS) is one of the 8 Best Genomics Stocks to Buy According to Analysts. On June 8, Cerus Corporation (NASDAQ:CERS) closed a new debt facility with MidCap Financial, providing up to $110 million. The firm combined a five-year term loan with an asset-backed revolving loan. The company said the refinancing will cut annual […]Cerus Corporation (CERS) Gets Upgraded to Buy Post Q1 by BTIG
Cerus Corporation (NASDAQ:CERS) is one of the best oversold growth stocks to invest in now. BTIG upgraded Cerus Corporation (NASDAQ:CERS) to Buy from Neutral on May 1, reiterating a $4 price target. The rating update came after the company announced its financial results for fiscal Q1 2026, with total revenue for the quarter reaching $59.9 million, […]Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer
CONCORD, Calif.--(BUSINESS WIRE)--Mar 16, 2026--
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cerus
Sign Up For FreeTo access detailed company insights
Headquartered in Concord, California, Cerus develops and commercializes the INTERCEPT Blood System, a pathogenreduction technology used by blood centers and hospitals to inactivate viruses, bacteria, and parasites in blood components (e.g., platelets and plasma), with additional programs in red blood cells.... Read More
